Clinical trial
The Efficacy and Safety of Resection Plus Neoadjuvant Hepatic Arterial Infusion Chemotherapy Compared With Resection Alone in Patients With Resectable Hepatocellular Carcinoma Beyond Milan Criteria
NCT03469479 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Resection Plus Neoadjuvant Hepatic Arterial Infusion Chemotherapy Compared With Resection Alone in Patients With Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 2, 2018
- Completion date
- March 2, 2023
- Enrollment
- 252 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma